Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novozymes TEDA Biopharma Facility on Track for Early 2011 Opening

publication date: Apr 13, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novozymes, the Danish manufacturer of enzymes, said its first biopharmaceutical manufacturing facility in China will be ready for operation in Q1 of 2011. The facility, which began construction a year ago, is being built in the Tianjin Economic-Technological Development Area (TEDA) at a cost of between $35 million and $50 million. More details...

Stock Symbol: (OTCPK: NVZMF; Copenhagen A/S: NZYM B)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...